King, Valerie A.

From: Roethig, Hans
Sent: Monday, August 05, 2002 12:41 PM
To: Ortrun Presting (E-mail)
Cc: Oey, Jan; King, Valerie A.
Subject: FW: EHCJLI/03/02-ACCORD Menthol

Sensitivity: Confidential

[redacted] AA01150_F2_05AUG2_2_Philip Morr...

[redacted] AA01150_05AUG02_ATTACHMENTS_Ph...

Dear Ortrun,
here is the revised protocol for the ACCORD JLI Menthol study. Please use also the comments Jan sent you for revising the Informed Consent. Please send us a copy of the IC, once you revised it.
Best regards
Hans J Roethig, MD, PhD, FCP, FFPM
Director Clinical Evaluation
Philip Morris USA
615 Maury Street
Richmond, VA 23224
Phone: (804) 274-3165
Fax: (804) 274-2891
Mobile phone: (804) 687-1655
e-mail: hans-juergen.roethig@PMUSA.com

-----Original Message-----
From: Michael Szwanek (402)437-4880 [mailto:Michael.Szwanek@mdsps.com]
Sent: Monday, August 05, 2002 12:40 PM
To: Hans-Juergen.Roethig@pmusa.com
Cc: jan.oey@pmusa.com; Kimberly Prchal; Robert Earl; Kirk Newland
Subject: EHCJLI/03/02-ACCORD Menthol
Sensitivity: Confidential

Hans,

Attached is the protocol and Selected Attachments dated August 5, 2002 for EHCJLI/03/02-ACCORD Menthol study to be conducted by PAREXEL. I have incorporated all of Amendment One changes into this version of the protocol so Amendment One is no longer valid or required. In addition I revised the IRB to Chesapeake Research Review, Inc. Another additional change was made for urine collection for 3-HPMA and NNAL and NNAL-glucuronide. We will now collect these samples in HDPE as it has been determine that silanized glass is no longer required.

Thanks,

Michael F. Szwanek, Pharm D., MBA
Senior Scientist, Study Design & Protocol Development
MDS Pharma Services - Lincoln, NE
michael.szwanek@mdsps.com
(402) 437-4880

PM3006787719

Source: https://www.industrydocuments.ucsf.edu/docs/mlmx0001